{"id":9437,"date":"2020-05-28T17:40:27","date_gmt":"2020-05-28T12:10:27","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9437"},"modified":"2024-09-18T13:17:58","modified_gmt":"2024-09-18T07:47:58","slug":"recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus","title":{"rendered":"Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK\u2019s anti-BCMA antibody receives a boost"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ff1add04af8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ff1add04af8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus\/#The_startup_focuses_on_glioblastoma_tumors_with_CAR-T_therapy\" >The startup focuses on glioblastoma tumors with CAR-T therapy.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus\/#AbCellera_grabs_USD_105_Million_for_series_B_funding_round\" >AbCellera grabs USD 105 Million for series B funding round.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus\/#Gilead_inks_USD_2_Billion_deal_with_Arcus\" >Gilead inks USD 2 Billion deal with Arcus.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus\/#GlaxoSmithKlines_anti-BCMA_antibody_receives_a_boost\" >GlaxoSmithKline\u2019s anti-BCMA antibody receives a boost.&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-the-startup-focuses-on-glioblastoma-tumors-with-car-t-therapy\"><span class=\"ez-toc-section\" id=\"The_startup_focuses_on_glioblastoma_tumors_with_CAR-T_therapy\"><\/span><strong>The startup focuses on glioblastoma tumors with CAR-T therapy.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T<\/a> technology that involves genetically modifying a patient\u2019s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted.<\/p>\n\n\n\n<p>The scientists at McMaster University and the University of Toronto have developed a<a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\"> CAR-T therapy<\/a> for the aggressive brain cancer <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-market-size\">glioblastoma<\/a>. It aided in reducing the burden of the tumour and enhanced survival in mouse models as published in the journal Cell Stem Cell.<\/p>\n\n\n\n<p>The researchers launched a startup known as Empirica Therapeutics, which targets to bring the CAR-T drug into clinical trials in recurrent glioblastoma patients by the year 2022. For each <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\">CAR-T<\/a> construct, T cells are modified to develop a particular structure known as a chimeric antigen receptor (CAR), which proffers the cells the ability to identify a specific protein on cancer cells. The two FDA-approved CAR-Ts, Novartis\u2019 Kymriah and Gilead Sciences\u2019 Yescarta, are directed toward CD19. The CAR-T cell Empirica is developing targets CD133, also known as prominin-1.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abcellera-grabs-usd-105-million-for-series-b-funding-round\"><span class=\"ez-toc-section\" id=\"AbCellera_grabs_USD_105_Million_for_series_B_funding_round\"><\/span><strong>AbCellera grabs USD 105 Million for series B funding round.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Canadian biotech AbCellera has grabbed a significant USD 105 million series B funding round as it focuses on boosting its antibody work and quest for new potential meds against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a>.<\/p>\n\n\n\n<p>Its supporters are Peter Thiel, PayPal founder and tech\/occasional life science investor, and Eli Lilly, which has helped it becoming a central figure in the fight against the pandemic.<\/p>\n\n\n\n<p>The biotech joined the race to create a therapy against the <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">SARS-CoV-2<\/a> virus by obtaining a blood sample from one of the first U.S. patients for recovery from the pathogen. Having gained the sample, AbCellera showed 5 million immune cells in quest of ones that made the functional antibodies that aided the patient to neutralize <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\">SARS-CoV-2<\/a>.<\/p>\n\n\n\n<p>The screening recognized 500 or so fully human antibody sequences. With the project now progressing to an evaluation of the antibodies\u2019 effectiveness against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">SARS-CoV-2<\/a>, AbCellera enlisted Lilly to keep the program moving forward.<\/p>\n\n\n\n<p>Under that agreement, AbCellera and Lilly will divide initial development costs. After that, Lilly will acquire and try to get the candidate via development, manufacturing and talks with regulators as soon as possible.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-inks-usd-2-billion-deal-with-arcus\"><span class=\"ez-toc-section\" id=\"Gilead_inks_USD_2_Billion_deal_with_Arcus\"><\/span><strong>Gilead inks USD 2 Billion deal with Arcus.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead Sciences is paying USD 175 million upfront with a USD 200 million equity investment weighted in. Arcus Biosciences could also catch up to USD 1.225 billion in opt-in and milestone payments to its present clinical product drugs.<\/p>\n\n\n\n<p>The deal highlights Gilead is joining giants like Merck and Roche in the race to bring an anti-TIGIT antibody to market that could be the future of immuno-oncology, while also benefitting a hand in the checkpoint inhibitor research space.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Arcus Biosciences has moved its anti-TIGIT candidate, AB154, into a phase 2 trial in patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\"><strong>non-small cell lung cancer<\/strong><\/a> recently. In the trial, Arcus expects AB154 shows improved efficacy of anti-PD-1 checkpoint inhibitors. The potential for the targeting of TIGIT, another immune checkpoint, to improve the efficacy of drugs like Merck\u2019s hit PD-1 Keytruda, has fascinated the interest.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-glaxosmithkline-s-anti-bcma-antibody-receives-a-boost\"><span class=\"ez-toc-section\" id=\"GlaxoSmithKlines_anti-BCMA_antibody_receives_a_boost\"><\/span><strong>GlaxoSmithKline\u2019s anti-BCMA antibody receives a boost.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>BCMA-targeting medicine of GlaxoSmithKline shrank tumors in one-third of patients with advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma<\/a>. The antibody-drug conjugate (ADC) is filling its case as the British drugmaker waits for the agency\u2019s decision now.<\/p>\n\n\n\n<p>The company will show seven more months\u2019 worth of data, which will show the response rate remained steady at 32%. Of the 97 patients that got the lower dose of the treatment, belantamab mafodotin, 31 had their tumors shrunk, and five patients saw them disappear.<\/p>\n\n\n\n<p>The essential phase 2 study investigated two doses of belantamab mafodotin around in 200 patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-refractory-multiple-myeloma-market\"><strong>multiple myeloma<\/strong><\/a>, who had returned after treatment or had not reacted to the treatment in the first place. The patients had attempted a median of seven other treatments, covering an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody-like Johnson &amp; Johnson\u2019s Darzalex. The response rates for both doses were similar. However, the study investigators suggested the lower dose for future work as it caused fewer side effects.&nbsp;<br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The startup focuses on glioblastoma tumors with CAR-T therapy. CAR-T technology that involves genetically modifying a patient\u2019s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted. The scientists at McMaster University and the University of Toronto have developed a CAR-T [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9445,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17997,18321,18391,985,18390,423,639,5789,16932],"industry":[17225],"therapeutic_areas":[17235,17229,17245],"class_list":["post-9437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abcellera","tag-advanced-multiple-myeloma","tag-arcus","tag-glaxosmithkline","tag-kymriah-and-gilead-sciences","tag-novartis","tag-pharma-news","tag-recent-pharma-news","tag-yescarta","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AbCellera raises $105M; Gilead&#039;s $2B deal; GSK&#039;s anti-BCMA antibody<\/title>\n<meta name=\"description\" content=\"The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera raises $105M; Gilead&#039;s $2B deal; GSK&#039;s anti-BCMA antibody\" \/>\n<meta property=\"og:description\" content=\"The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-28T12:10:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:47:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/28173454\/News-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbCellera raises $105M; Gilead's $2B deal; GSK's anti-BCMA antibody","description":"The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus","og_locale":"en_US","og_type":"article","og_title":"AbCellera raises $105M; Gilead's $2B deal; GSK's anti-BCMA antibody","og_description":"The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-05-28T12:10:27+00:00","article_modified_time":"2024-09-18T07:47:58+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/28173454\/News-4.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus","name":"AbCellera raises $105M; Gilead's $2B deal; GSK's anti-BCMA antibody","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/28173454\/News-4.jpg","datePublished":"2020-05-28T12:10:27+00:00","dateModified":"2024-09-18T07:47:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/28173454\/News-4.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/28173454\/News-4.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/28173454\/News-4-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbCellera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arcus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kymriah And Gilead Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Yescarta<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbCellera<\/span>","<span class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Arcus<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Kymriah And Gilead Sciences<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Yescarta<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 28, 2020","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on May 28, 2020 5:40 pm","modified":"Updated on Sep 18, 2024 1:17 pm"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9437"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9437\/revisions"}],"predecessor-version":[{"id":29592,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9437\/revisions\/29592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9445"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9437"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9437"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}